Enveric Biosciences Canada Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Aug 2041
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 25, 2027The maintenance fee for C4-CARBONOTHIOATE-SUBSTITUTED Tryptamine Derivatives and Methods of Using (US 11,707,447) comes due Jan 25, 2027. Unpaid by Jul 26, 2027, it lapses early.
- 2 fees due Mar 5 to 12, 2027 · next Mar 5
- 2 fees due Jun 19, 2027
- 1 fee due Jul 2, 2027The maintenance fee for Aminated psilocybin derivatives and methods of using (US 11,858,895) comes due Jul 2, 2027. Unpaid by Jan 3, 2028, it lapses early.
- 2 fees due Aug 6, 2027
- 2 fees due Sep 5 to 19, 2027 · next Sep 5
- 1 fee due Oct 2, 2027The maintenance fee for C4-CARBONOTHIOATE-SUBSTITUTED Tryptamine Derivatives and Methods of Using (US 11,945,778) comes due Oct 2, 2027. Unpaid by Apr 3, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,891,360 | Glycosylated psilocybin derivatives and methods of using In force · USPTO record | In force | USPTO record | |
| US 11,998,557 | Halogenated Psilocybin Derivatives and Methods of Using In force · High confidence | In force | High confidence | |
| US 12,138,276 | Halogenated Psilocybin Derivatives and Methods of Using In force · High confidence | In force | High confidence | |
| US 12,187,679 | Hydroxylated psilocybin derivatives and methods of using In force · USPTO record | In force | USPTO record | |
| US 11,931,338 | Nitrilated psilocybin derivatives and methods of using In force · USPTO record | In force | USPTO record | |
| US 11,752,130 | Carboxylated Psilocybin Derivatives and Methods of Using In force · High confidence | In force | High confidence | |
| US 11,918,594 | Multi-Substituent Psilocybin Derivatives and Methods of Using In force · High confidence | In force | High confidence | |
| US 12,605,361 | Carboxylated Psilocybin Derivatives and Methods of Using In force · High confidence | In force | High confidence | |
| US 11,845,727 | Aldehyde and ketone derivatives of psilocybin and methods of using In force · USPTO record | In force | USPTO record | |
| US 11,858,895 | Aminated psilocybin derivatives and methods of using In force · USPTO record | In force | USPTO record |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
9 pending